Cervical Cancer Vaccine Trial Generates Huge Headlines

THIS IS AN UPDATE ABOUT THE RACE to be first to market a vaccine to prevent cervical cancer. Merck & Co. is currently in the lead. On October 6, 2005, Merck released results of a trial that is part of a phase III study of its vaccine, called GARDASIL™ (a “quadrivalent human papillomavirus types 6, …

Cervical Cancer Vaccine Trial Generates Huge Headlines Read More »

To access this post, you must purchase The Dark Report.

Cervical Cancer Vaccine Trial Generates Huge Headlines

Because of its potential to prevent cancer, HPV vaccine is closely-watched by media

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month